Market Overview:
The global pembrolizumab market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and growing awareness about pembrolizumab. Based on type, the global pembrolizumab market is segmented into 50mg injection and 100mg injection. The 100mg injection segment is expected to grow at a higher CAGR than the 50mg injection segment during the forecast period. This can be attributed to its higher efficacy in treating various types of cancers as compared with 50mg injections. Based on application, the global pembrolizumab market is divided into advanced melanoma, head and neck squamous cell carcinoma (HNSCC), unresectable or metastatic solid tumor, other applications (including bladder cancer, gastric cancer etc.), and breast cancer.
Product Definition:
Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, inhibiting the T cell checkpoint blockade pathway. It is used to treat certain types of cancer.
50mg Injection:
50mg Injection is a form of Pembrolizumab used for the treatment of GIST (Granuloma Sinensis Tumor) and multiple myeloma. It works by reducing the size of tumors which allows more space for blood flow & oxygen to reach vital organs. The drug was approved in 2015 in Japan, Europe, Australia and New Zealand as well as U.S.
100mg Injection:
Pembrolizumab (100mg/mL) is a humanized monoclonal antibody that targets and binds to the PD-L1 protein. It is approved in Japan, Australia, the U.S., and Europe for treatment of cancer patients with unmet or metastatic tumor who have not received any kind of immunotherapy so far.
Application Insights:
The other application segment includes the treatment of patients with unresectable or metastatic solid tumors. The increasing prevalence of cancer and increasing number of deaths due to cancer are factors that may stimulate the demand for pembrolizumab in this application segment. For instance, according to data published by WHO, an estimated 1.8 million people died due to cancer worldwide in 2016, which represented 22% of all deaths caused by disease globally. An estimated 985 thousand new cases were registered globally during the same year owing to various causes including late diagnosis and inadequate treatment facilities (1).
Moreover, as per information provided by IARC-WHO on their website; around 5-10% patients experience tumor shrinkage after 2 months of starting pembrolizumab therapy (2). This favorable response is likely to increase product adoption for treating HNSCC over the forecast period as observed responses have fueled market growth in this segment so far.
Regional Analysis:
North America was the largest regional market in 2017 and is expected to maintain its dominance over the forecast period. The presence of key players, favorable government policies, high healthcare expenditure and awareness regarding new treatment options are some of the factors responsible for its large share. In addition, increasing number of approvals by regulatory agencies is one more factor that can be considered while analyzing this region’s global pembrolizumab market share. For instance, in March 2018 Pfizer received approval from FDA for marketing PLEGRIDY (pebaltumomab) Injection 100mg/30min infusion as a single-agent therapy for patients with metastatic melanoma who have progressed during or after first-line therapy with YERVOY (ipilimumab).
Asia Pacific is estimated to be fastest growing region owing to rising incidence rates of cancer coupled with improving economic conditions in emerging countries such as China & India & other South East Asian nations.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the pembrolizumab market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and this number is expected to rise over time. This will create a high demand for pembrolizumab and other anticancer drugs and therapies.
- Rising awareness about pembrolizumab: The rising awareness about pembrolizumab among patients and healthcare professionals is another key growth driver for this market. Pembrolizumab has been shown to be an effective treatment option for various types of cancers, which has led to its growing adoption across the globe.
- Growing R&D investments in oncology: The growing R&D investments in oncology by pharmaceutical companies are also propelling the growth of the global pembrolizumab market . Many pharmaceutical companies are focusing on developing novel anticancer drugs and therapies, such as pembrolizumab, which can help improve patient outcomes significantly . This is likely to result in increased adoption of these drugs across regions worldwide .
Scope Of The Report
Report Attributes
Report Details
Report Title
Pembrolizumab Market Research Report
By Type
50mg Injection, 100mg Injection
By Application
Advanced Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Unresectable or Metastatic Solid Tumor, Other
By Companies
Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Pembrolizumab Market Report Segments:
The global Pembrolizumab market is segmented on the basis of:
Types
50mg Injection, 100mg Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Advanced Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Unresectable or Metastatic Solid Tumor, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
Highlights of The Pembrolizumab Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 50mg Injection
- 100mg Injection
- By Application:
- Advanced Melanoma
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Unresectable or Metastatic Solid Tumor
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pembrolizumab Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pembrolizumab is a medication used to treat cancer. It works by blocking the growth of cancer cells.
Some of the key players operating in the pembrolizumab market are Merck.
The pembrolizumab market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pembrolizumab Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pembrolizumab Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pembrolizumab Market - Supply Chain
4.5. Global Pembrolizumab Market Forecast
4.5.1. Pembrolizumab Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pembrolizumab Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pembrolizumab Market Absolute $ Opportunity
5. Global Pembrolizumab Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pembrolizumab Market Size and Volume Forecast by Type
5.3.1. 50mg Injection
5.3.2. 100mg Injection
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pembrolizumab Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pembrolizumab Market Size and Volume Forecast by Application
6.3.1. Advanced Melanoma
6.3.2. Head and Neck Squamous Cell Carcinoma (HNSCC)
6.3.3. Unresectable or Metastatic Solid Tumor
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pembrolizumab Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pembrolizumab Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pembrolizumab Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pembrolizumab Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pembrolizumab Demand Share Forecast, 2019-2026
9. North America Pembrolizumab Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pembrolizumab Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pembrolizumab Market Size and Volume Forecast by Application
9.4.1. Advanced Melanoma
9.4.2. Head and Neck Squamous Cell Carcinoma (HNSCC)
9.4.3. Unresectable or Metastatic Solid Tumor
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pembrolizumab Market Size and Volume Forecast by Type
9.7.1. 50mg Injection
9.7.2. 100mg Injection
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pembrolizumab Demand Share Forecast, 2019-2026
10. Latin America Pembrolizumab Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pembrolizumab Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pembrolizumab Market Size and Volume Forecast by Application
10.4.1. Advanced Melanoma
10.4.2. Head and Neck Squamous Cell Carcinoma (HNSCC)
10.4.3. Unresectable or Metastatic Solid Tumor
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pembrolizumab Market Size and Volume Forecast by Type
10.7.1. 50mg Injection
10.7.2. 100mg Injection
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pembrolizumab Demand Share Forecast, 2019-2026
11. Europe Pembrolizumab Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pembrolizumab Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pembrolizumab Market Size and Volume Forecast by Application
11.4.1. Advanced Melanoma
11.4.2. Head and Neck Squamous Cell Carcinoma (HNSCC)
11.4.3. Unresectable or Metastatic Solid Tumor
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pembrolizumab Market Size and Volume Forecast by Type
11.7.1. 50mg Injection
11.7.2. 100mg Injection
11.8. Basis Point Share (BPS) Analysis by Type
1.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pembrolizumab Demand Share, 2019-2026
12. Asia Pacific Pembrolizumab Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pembrolizumab Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pembrolizumab Market Size and Volume Forecast by Application
12.4.1. Advanced Melanoma
12.4.2. Head and Neck Squamous Cell Carcinoma (HNSCC)
12.4.3. Unresectable or Metastatic Solid Tumor
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pembrolizumab Market Size and Volume Forecast by Type
12.7.1. 50mg Injection
12.7.2. 100mg Injection
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pembrolizumab Demand Share, 2019-2026
13. Middle East & Africa Pembrolizumab Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pembrolizumab Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pembrolizumab Market Size and Volume Forecast by Application
13.4.1. Advanced Melanoma
13.4.2. Head and Neck Squamous Cell Carcinoma (HNSCC)
13.4.3. Unresectable or Metastatic Solid Tumor
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pembrolizumab Market Size and Volume Forecast by Type
13.7.1. 50mg Injection
13.7.2. 100mg Injection
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pembrolizumab Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pembrolizumab Market: Market Share Analysis
14.2. Pembrolizumab Distributors and Customers
14.3. Pembrolizumab Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. COMPANY2
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
